静注CD_3AK细胞治疗晚期肝癌的初步观察

A Preliminary Observation on Infravenows CD 3AK Cells in the Treatment of Late Hepatoma

用培养７ｄ以上的ＣＤ３单抗激活的杀伤细胞（ＣＤ３ＡＫ细胞）加ｒＩＬ－２静注治疗晚期肝癌２１例，其中ＣＲ１例，ＰＲ５例，临床有效率以ＣＲ＋ＰＲ计为２８．９％，明显高于ＬＡＫ细胞抗肝癌疗效。治疗后大多数病人临床症状改善，生活质量提高，外周血ＣＤ３＋、ＣＤ４＋升高，ＣＤ８＋下降，ＣＤ４＋／ＣＤ８＋升高，统计学检验均有显著差异。患者血清ＳＩＬ－２Ｒ水平明显降低（Ｐ＜０．０１）。结果提示：静脉注射ＣＤ３ＡＫ细胞可以降低肝癌患者机体瘤负荷，增强机体免疫力，从而对晚期肝癌产生较好的治疗效果。

Twenty one cases of late hepatoma were treated with CD 3 monoclonal antibody activated killer (CD 3AK) cells having been cultured for over seven days blus IL 2 by intravenous injection. Among them one case got complete remission ,five got partial remission and the total effective rate was 28.9% recorded by CR+PR,obviously higher than that of LAK cell. After treatment,most patients had clinical symptoms improved,life quality increased,In their peripheral blood the level of CD 3 +,CD 4 +increased, CD 8 +decreased,CD 4 +/CD 8 +increased,with significant difference statistically. The level of SIL 2R in patient serum decreased obviously (P<0 01) The results suggest that intravenous in jection CD 3AK cells can reduce the patient’s load of tumor,strengthen immunity and thence better therapeutic effect in late hepatoma may be cbtained.